.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Queensland Health
Cerilliant
Fuji
Dow
Covington
Medtronic
Chinese Patent Office
Citi
Harvard Business School

Generated: July 26, 2017

DrugPatentWatch Database Preview

DALMANE Drug Profile

« Back to Dashboard

What is the patent landscape for Dalmane, and what generic Dalmane alternatives are available?

Dalmane is a drug marketed by Valeant Pharm Intl and is included in one NDA.

The generic ingredient in DALMANE is flurazepam hydrochloride. There are four drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the flurazepam hydrochloride profile page.

Summary for Tradename: DALMANE

Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list14
Patent Applications: see list3,319
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DALMANE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl
DALMANE
flurazepam hydrochloride
CAPSULE;ORAL016721-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm Intl
DALMANE
flurazepam hydrochloride
CAPSULE;ORAL016721-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DALMANE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm Intl
DALMANE
flurazepam hydrochloride
CAPSULE;ORAL016721-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Valeant Pharm Intl
DALMANE
flurazepam hydrochloride
CAPSULE;ORAL016721-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Dow
Healthtrust
Medtronic
AstraZeneca
Deloitte
Fuji
Moodys
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot